Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus
Open accessAbstract
AIMS: To determine the effects of empagliflozin on adiposity indices among patients with type 2 diabetes mellitus. METHODS: Changes in weight, waist circumference, estimated total body fat, index of central obesity and visceral adiposity index were assessed using analysis of covariance and testing of treatment by strata for age, sex and baseline waist circumference in patients with type 2 diabetes mellitus randomized to blinded treatment with empagliflozin versus placebo in clinical trials of 12 weeks (cohort 1) or 24 weeks (cohort 2) duration. RESULTS: This study comprised 3300 patients (cohort 1, N = 823; cohort 2, N = 2477). Empagliflozin reduced weight, waist circumference and adiposity indices versus placebo in both cohorts. Adjusted mean (95% confidence interval) change from baseline in empagliflozin versus placebo was -1.7 kg (-2.1 to -1.4 kg) and -1.9 kg (-2.1 to -1.7 kg) for body weight (p < 0.001); -1.3 cm (-1.8 to -0.7 cm) and -1.3 cm (-1.7 to -1.0 cm) for waist circumference (p < 0.001); -0.2% (-0.7% to 0.3%; p = 0.45) and -0.3% (-0.7% to 0.0%; p = 0.08) for estimated total body fat; -0.007 (-0.011 to -0.004) and -0.008 (-0.010 to -0.006) for index of central obesity (p < 0.001); and -0.3 (-0.5 to 0.0; p = 0.07) and -0.4 (-0.7 to -0.1; p = 0.003) for visceral adiposity index in cohorts 1 and 2, respectively. Adipose reductions were seen across most age, sex and waist circumference subgroups. CONCLUSION: Empagliflozin significantly reduced weight and adiposity indices with the potential to improve cardiometabolic risk among patients with type 2 diabetes mellitus.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
SGLT2 inhibitors have metabolic effects, including lowering plasma glucose, and modest effects on body weight and blood pressure.
“Sodium glucose co-transporter 2 inhibitors have metabolic effects, including lowering of plasma glucose levels, and (modest) effects on body weight and blood pressure.11”
From The cardioprotective effects of semaglutide exceed those of dietary weight loss in mice with HFpEF (2023) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315 · see citing works
Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes
Schauer, P. R., Kashyap, S. R., Wolski, K., Brethauer, S. A., Kirwan, J. P., Pothier, C. E., Thomas, S., Abood, B., Nissen, S. E., & Bhatt, D. L. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200225 · Cited by 2,164 · see citing works
Amato, M. C., Giordano, C., Galia, M., Criscimanna, A., Vitabile, S., Midiri, M., Galluzzo, A., & for the AlkaMeSy Study Group (2010) · Diabetes Care · doi:10.2337/dc09-1825 · Cited by 1,751 · see citing works
Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk
Després, J.-P., Lemieux, I., Bergeron, J., Pibarot, P., Mathieu, P., Larose, E., Rodés-Cabau, J., Bertrand, O. F., & Poirier, P. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.159228 · Cited by 1,589 · see citing works
Cefalu, W. T., Leiter, L. A., Yoon, K., Arias, P., NISKANEN, L. K., Xie, J., Balis, D. A., Canovatchel, W. J., & Meininger, G. E. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60683-2 · Cited by 723 · see citing works
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
(2016) · New England Journal of Medicine · doi:10.1056/nejmc1600827 · Cited by 700 · see citing works
Bolinder, J., Ljunggren, Ö., Johansson, L. O. M., Wilding, J. P. H., Langkilde, A., Sjöström, C. D., Sugg, J. E., & Parikh, S. J. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12189 · Cited by 484 · see citing works
Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension
Tikkanen, I., Narko, K., Zeller, C., Green, A., Salsali, A., Broedl, U. C., & Woerle, H. J. (2015) · Diabetes Care · doi:10.2337/dc14-1096 · Cited by 468 · see citing works
Roden, M., Weng, J., Eilbracht, J., Delafont, B., Kim, G., Woerle, H. J., & Broedl, U. C. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70084-6 · Cited by 451 · see citing works
Häring, H., Merker, L., Seewaldt-Becker, E., Weimer, M. S., Meinicke, T. W., Broedl, U. C., Woerle, H. J., & on behalf of the EMPA-REG MET Trial Investigators (2014) · Diabetes Care · doi:10.2337/dc13-2105 · Cited by 401 · see citing works
SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials
Inzucchi, S. E., Zinman, B., Wanner, C., Ferrari, R., FITCHETT, D. H., Hantel, S., Espadero, R.-M., Woerle, H. J., Broedl, U. C., & Johansen, O. E. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114559852 · Cited by 399 · see citing works
Kovács, C. S., Seshiah, V., Swallow, R., Jones, R., Rattunde, H., Woerle, H. J., Broedl, U. C., & on behalf of the EMPA‐REG PIO™ trial investigators (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12188 · Cited by 389 · see citing works
Ridderstråle, M., Andersen, K. R., Zeller, C., Kim, G., Woerle, H. J., & Broedl, U. C. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70120-2 · Cited by 379 · see citing works
Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes
Häring, H., Merker, L., Seewaldt-Becker, E., Weimer, M. S., Meinicke, T. W., Woerle, H. J., Broedl, U. C., & on behalf of the EMPA-REG METSU Trial Investigators (2013) · Diabetes Care · doi:10.2337/dc12-2673 · Cited by 374 · see citing works
An anthropometric estimation of body density and lean body weight in young men.
Wilmore, J. H., & Behnke, A. R. (1969) · Journal of Applied Physiology · doi:10.1152/jappl.1969.27.1.25 · Cited by 310 · see citing works
Chaston, T. B., & Dixon, J. B. (2008) · International Journal of Obesity · doi:10.1038/sj.ijo.0803761 · Cited by 300 · see citing works
An Anthropometric Estimation of Body Density and Lean Body Weight in Young Women
Wilmore, J. H., & Behnke, A. R. (1970) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/23.3.267 · Cited by 240 · see citing works
Effects of Bariatric Surgery on Cardiac Ectopic Fat
Gaborit, B., Jacquier, A., Kober, F., Abdesselam, I., Cuisset, T., Boullu-Ciocca, S., Emungania, O., Alessi, M.-C., Clément, K., Bernard, M., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.06.016 · Cited by 205 · see citing works
Changing definitions of metabolic syndrome
Parikh, R., & Mohan, V. (2011) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.91175 · Cited by 184 · see citing works
Index of central obesity – A novel parameter
Parikh, R. M., Joshi, S., Menon, P. S. N., & Shah, N. S. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2006.10.038 · Cited by 93 · see citing works
Ford, E. S. (2011) · Journal of Diabetes · doi:10.1111/j.1753-0407.2011.00148.x · Cited by 79 · see citing works
Bays, H. E. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.08.029 · Cited by 73 · see citing works
Index of Central Obesity Is Better Than Waist Circumference in Defining Metabolic Syndrome
Parikh, R. M., Joshi, S., & Pandia, K. (2009) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2008.0102 · Cited by 36 · see citing works
Neeland, I. J., McGuire, D. K., Eliasson, B., Ridderstråle, M., Zeller, C., Woerle, H. J., Broedl, U. C., & Johansen, O. E. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0146-7 · Cited by 23 · see citing works
Luo, W., Guo, Z., Wu, M., Hao, C., Zhou, Z., & Yao, X. (2014) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000000039 · Cited by 7 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Yurista, S. R., Silljé, H. H. W., Oberdorf‐Maass, S. U., Schouten, E., Pávez, M., Hillebrands, J., van Goor, H., van Veldhuisen, D. J., de Boer, R. A., & Westenbrink, B. D. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1473 · Cited by 322 · see citing works
Gliflozins in the Management of Cardiovascular Disease
Braunwald, E. (2022) · New England Journal of Medicine · doi:10.1056/nejmra2115011 · Cited by 268 · see citing works
Body Weight Considerations in the Management of Type 2 Diabetes
Apovian, C. M., Okemah, J., & O'Neil, P. M. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0824-8 · Cited by 242 · see citing works
Schork, A., Saynisch, J., Vosseler, A., Jaghutriz, B. A., Heyne, N., Peter, A., Häring, H., Stefan, N., Fritsche, A., & Artunç, F. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0852-y · Cited by 228 · see citing works
The Evolving Understanding and Approach to Residual Cardiovascular Risk Management
Dhindsa, D. S., Sandesara, P. B., Shapiro, M. D., & Wong, N. D. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00088 · Cited by 200 · see citing works
Hierro‐Bujalance, C., Infante‐Garcia, C., del Marco, À., Herrera, M., Carranza-Naval, M. J., Suarez, J., Alves-Martínez, P., Lubián‐López, S. P., & Garcı́a-Alloza, M. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00607-4 · Cited by 186 · see citing works
Chehrehgosha, H., Sohrabi, M. R., Ismail-Beigi, F., Malek, M., Reza Babaei, M., Zamani, F., Ajdarkosh, H., Khoonsari, M., Fallah, A. E., & Khamseh, M. E. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01011-3 · Cited by 173 · see citing works
Byrne, N. J., Parajuli, N., Levasseur, J. L., Boisvenue, J., Beker, D. L., Masson, G., Fedak, P. W. M., Verma, S., & Dyck, J. R. B. (2017) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2017.07.003 · Cited by 172 · see citing works
Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload
Packer, M., Anker, S. D., Butler, J., Filippatos, G. S., Ferreira, J. P., Pocock, S., Sattar, N. A., Brueckmann, M., Jamal, W., Cotton, D., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.01.033 · Cited by 172 · see citing works
Sattar, N. A., FITCHETT, D. H., Hantel, S., George, J. T., & Zinman, B. (2018) · Diabetologia · doi:10.1007/s00125-018-4702-3 · Cited by 173 · see citing works
Lahnwong, C., Chattipakorn, S. C., & Chattipakorn, N. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0745-5 · Cited by 161 · see citing works
Body composition changes in diabetes and aging
Al‐Sofiani, M. E., Ganji, S. S., & Kalyani, R. R. (2019) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2019.03.007 · Cited by 158 · see citing works
Kusaka, H., Koibuchi, N., Hasegawa, Y., Ogawa, H., & Kim‐Mitsuyama, S. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0473-7 · Cited by 159 · see citing works
Empagliflozin: A Review in Type 2 Diabetes
Frampton, J. E. (2018) · Drugs · doi:10.1007/s40265-018-0937-z · Cited by 151 · see citing works
Kloock, S., Ziegler, C. G., & Dischinger, U. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108549 · Cited by 157 · see citing works
Kaku, K., Lee, J., Mattheus, M., Kaspers, S., George, J. T., Woerle, H., & on behalf of the EMPA-REG OUTCOME® Investigators (2016) · Circulation Journal · doi:10.1253/circj.cj-16-1148 · Cited by 128 · see citing works
Javed, Z., Papageorgiou, M., Deshmukh, H., Rigby, A. S., Qamar, U., Abbas, J., Khan, A. Y., Kilpatrick, E. S., Atkin, S. L., & Sathyapalan, T. (2019) · Clinical Endocrinology · doi:10.1111/cen.13968 · Cited by 121 · see citing works
Packer, M. (2021) · JACC Heart Failure · doi:10.1016/j.jchf.2021.05.019 · Cited by 116 · see citing works
Ortega, R., Collado, A., Selles, F., Navarro, H. G., Sanz, M., Real, J. T., & Piqueras, L. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.312659 · Cited by 102 · see citing works
SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice
Wilding, J. P. H., Fernando, K., Milne, N., Evans, M., Ali, A., Bain, S. C., Hicks, D., James, J., Newland‐Jones, P., Patel, D., et al. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0471-8 · Cited by 97 · see citing works
Neeland, I. J., Eliasson, B., Kasai, T., Marx, N., Zinman, B., Inzucchi, S. E., Wanner, C., Zwiener, I., Wojeck, B. S., Yaggi, H. K., et al. (2020) · Diabetes Care · doi:10.2337/dc20-1096 · Cited by 93 · see citing works
He, Y., Haynes, W., Meyers, C. D., Amer, A., Zhang, Y., Mahling, P., Mendonza, A. E., Ma, S., Chutkow, W., & Bachman, E. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13654 · Cited by 81 · see citing works
The cardioprotective effects of semaglutide exceed those of dietary weight loss in mice with HFpEF
Withaar, C., Meems, L. M. G., Nollet, E. E., Schouten, E. M., Schroeder, M. A., Knudsen, L. B., Niss, K., Madsen, C. T., Hoegl, A., Mazzoni, G., et al. (2023) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2023.05.012 · Cited by 74 · see citing works
Cardiovascular and Renal Benefits of SGLT2 Inhibitors: A Narrative Review
Rabizadeh, S., Nakhjavani, M., & Esteghamati, A. (2019) · Intern J Endocrinol Metab · doi:10.5812/ijem.84353 · Cited by 70 · see citing works
A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications
Haddad, F., Dokmak, G., Bader, M., & Karaman, R. (2023) · Life · doi:10.3390/life13041012 · Cited by 67 · see citing works
Seidu, S., Alabraba, V., Davies, S., Newland‐Jones, P., Fernando, K., Bain, S. C., Diggle, J., Evans, M., James, J., Kanumilli, N., et al. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01550-5 · Cited by 65 · see citing works
Obesity medications in development
Rebello, C. J., & Greenway, F. L. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1705277 · Cited by 62 · see citing works
Guo, M., Gu, J., Teng, F., Chen, J., Ma, X., Chen, Q., Pu, Y., Jiang, Z., Long, Y., & Xu, Y. (2020) · Endocrine · doi:10.1007/s12020-019-02175-6 · Cited by 60 · see citing works
Sleep Apnea and Cardiovascular Risk in Patients with Prediabetes and Type 2 Diabetes
Paschou, S. Α., Bletsa, E., Saltiki, K., Kazakou, P., Kantreva, K., Katsaounou, P. A., Rovina, N., Trakada, G., Bakakos, P., Vlachopoulos, C. V., et al. (2022) · Nutrients · doi:10.3390/nu14234989 · Cited by 64 · see citing works
Kayano, H., Koba, S., Hirano, T., Matsui, T., Fukuoka, H., Tsuijita, H., Tsukamoto, S., Hayashi, T., Toshida, T., Watanabe, N., et al. (2020) · Circulation Journal · doi:10.1253/circj.cj-20-0341 · Cited by 60 · see citing works
The heart failure burden of type 2 diabetes mellitus—a review of pathophysiology and interventions
Ofstad, A. P., Atar, D., Gullestad, L. L., Langslet, G., & Johansen, O. E. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9685-0 · Cited by 59 · see citing works
Busch, R. S., & Kane, M. P. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1342509 · Cited by 57 · see citing works
Abraham, W. T., Ponikowski, P. P., Brueckmann, M., Zeller, C., Macesic, H., Peil, B., Brun, M., Ustyugova, A., Jamal, W., Salsali, A., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1486 · Cited by 55 · see citing works
Liu, Y., Xu, J., Wu, M., Xu, B., & Kang, L. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01430-y · Cited by 49 · see citing works
Risks vs Benefits for SGLT2 Inhibitor Medications.
Pittampalli, S., Upadyayula, S., Mekala, H. M., & Lippmann, S. (2018) · Europe PMC (PubMed Central) · Cited by 43 · see citing works
Effects of sodium glucose co-transporter 2 inhibitors on the kidney
Rocha, N. D. A., Neeland, I. J., McCullough, P. A., Toto, R. D., & McGuire, D. K. (2018) · Diabetes and Vascular Disease Research · doi:10.1177/1479164118783756 · Cited by 41 · see citing works
Emerging roles of sodium–glucose cotransporter 2 inhibitors in cardiology
Tanaka, A., & Node, K. (2016) · Journal of Cardiology · doi:10.1016/j.jjcc.2016.10.019 · Cited by 40 · see citing works
Liu, Y., Wu, M., Xu, B., & Kang, L. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s309427 · Cited by 40 · see citing works
Bays, H. E., Kozlovski, P., Shao, Q., Proot, P., & Keefe, D. (2020) · Obesity · doi:10.1002/oby.22764 · Cited by 41 · see citing works
Papaetis, G. S. (2023) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad/161170 · Cited by 40 · see citing works
Zhang, Z., Ni, L., Zhang, L., Zha, D., Hu, C., Zhang, L., Feng, H. A., Wei, X., & Wu, X. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s289712 · Cited by 38 · see citing works
SGLT2 inhibition and heart failure—current concepts
da Silva, J. C., Durães, A. R., Abreu, M., Rocha, N. A., & Roever, L. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9703-2 · Cited by 37 · see citing works
Palanisamy, S., Yien, E. L. H., Shi, L., Yi, L., Qi, S. H., Soon, L., Lun, T. W., & Chen, Y. N. (2018) · Pharmacy · doi:10.3390/pharmacy6030057 · Cited by 37 · see citing works
Muzurović, E., & Mikhailidis, D. P. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1795132 · Cited by 35 · see citing works
McEwan, P., Morgan, A. R., Boyce, R., Bergenheim, K., Gause‐Nilsson, I. A. M., Bhatt, D. L., Leiter, L. A., Johansson, P. A., Mosenzon, O., Cahn, A., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14308 · Cited by 34 · see citing works
DPP4 inhibitors and cardiovascular outcomes: safety on heart failure
Xia, C. Q., Goud, A., D’Souza, J., Dahagam, C., Rao, X., Rajagopalan, S., & Zhong, J. (2017) · Heart Failure Reviews · doi:10.1007/s10741-017-9617-4 · Cited by 34 · see citing works
Inzucchi, S. E., Davies, M. J., Khunti, K. K., Trivedi, P., George, J. T., Zwiener, I., Johansen, O. E., & Sattar, N. A. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14234 · Cited by 34 · see citing works
Xiang, B., Zhao, X.-Y., & Zhou, X. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01266-x · Cited by 35 · see citing works
Impact of empagliflozin in patients with diabetes and heart failure
Pham, D. D., Rocha, N. D. A., McGuire, D. K., & Neeland, I. J. (2016) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2016.07.008 · Cited by 32 · see citing works
Yabe, D., Shiki, K., Suzaki, K., Meinicke, T. W., Kotobuki, Y., Nishida, K., Clark, D., Yasui, A., & Seino, Y. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-045844 · Cited by 30 · see citing works
Vaziri, Z., Saleki, K., Aram, C., Alijanizadeh, P., Pourahmad, R., Azadmehr, A., & Ziaei, N. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115686 · Cited by 29 · see citing works
Nakagaito, M., Joho, S., Ushijima, R., Nakamura, M., & Kinugawa, K. (2019) · Circulation Reports · doi:10.1253/circrep.cr-19-0070 · Cited by 29 · see citing works
Klimontov, V. V., Korbut, A. I., Taskaeva, I. S., Bgatova, N. P., Dashkin, M. V., Орлов, Н. Б., Khotskina, А. S., Zavyalov, E. L., & Klein, T. (2020) · World Journal of Diabetes · doi:10.4239/wjd.v11.i12.596 · Cited by 28 · see citing works
Bilgin, S., Kurtkulağı, Ö., Duman, T. T., Tel, B. M. A., Kahveci, G. B., Kiran, M., Erge, E., & Aktaş, G. (2021) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-021-02761-6 · Cited by 28 · see citing works
Neeland, I. J., Rocha, N. D. A., Hughes, C., Ayers, C. R., Malloy, C. R., & Jin, E. S. (2020) · Obesity · doi:10.1002/oby.22854 · Cited by 28 · see citing works
Early combination therapy with SGLT2i and GLP ‐1 RA or dual GIP / GLP ‐1 RA in type 2 diabetes
Vale, C., Lourenço, I. M., Jordan, G., Golovaty, I., Torres, H., Moin, T., Buysschaert, M., Neves, J. S., & Bergman, M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16077 · Cited by 29 · see citing works
Liu, X., Chen, Y., Liu, T., Cai, L., Yang, X., & Mou, C. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1115321 · Cited by 27 · see citing works
Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus
Budoff, M. J., & Wilding, J. P. H. (2017) · International Journal of Clinical Practice · doi:10.1111/ijcp.12948 · Cited by 27 · see citing works
Zhao, D., Liu, H., & Dong, P. (2018) · Journal of Human Hypertension · doi:10.1038/s41371-018-0134-2 · Cited by 26 · see citing works
Ji, Q., Ji, L., Mu, Y., Zhao, J., Zinman, B., Wanner, C., George, J. T., Zwiener, I., Ueki, K., Yokote, K., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14415 · Cited by 26 · see citing works
Sinha, S., Sonali, Garg, V., Thapa, S., Singh, S. K., Chauhan, M., Dutt, R., & Singh, R. P. (2022) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2022.2108829 · Cited by 25 · see citing works
Neeland, I. J., McGuire, D. K., Eliasson, B., Ridderstråle, M., Zeller, C., Woerle, H. J., Broedl, U. C., & Johansen, O. E. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0146-7 · Cited by 23 · see citing works
SGLT inhibitors for improving Healthspan and lifespan
O’Keefe, J. H., Weidling, R., O’Keefe, E. L., & Franco, W. G. (2023) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2023.10.003 · Cited by 24 · see citing works
Zheng, X., Qu, Q., Jiang, X., Wang, Z., Tang, C., & Sun, J. (2020) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-020-00441-x · Cited by 22 · see citing works
SGLT-2 inhibitors in obesity and its associated cardiometabolic disorders: where do we stand?
Vallianou, N. G., Tsilingiris, D., Kounatidis, D. C., Lempesis, I. G., Karampela, Ι., & Dalamaga, Μ. (2022) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16342 · Cited by 21 · see citing works
Yoon, K., Nishimura, R., Lee, J., Crowe, S., Salsali, A., Hach, T., & Woerle, H. J. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12699 · Cited by 21 · see citing works
Papaetis, G. S. (2021) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad.2021.105314 · Cited by 22 · see citing works
Dedemen, B., Duman, T. T., Dedemen, M. M., & Aktaş, G. (2024) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2024.07.016 · Cited by 20 · see citing works
A Safety Evaluation of Empagliflozin for the Treatment of Type 2 Diabetes
Neeland, I. J., Salahuddin, U., & McGuire, D. K. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1135900 · Cited by 20 · see citing works
The EMPA-REG outcome study: critical appraisal and potential clinical implications
Perseghin, G., & Solini, A. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0403-8 · Cited by 20 · see citing works
Empagliflozin restores cardiac metabolic flexibility in diet-induced obese C57BL6/J mice
Xie, B., Ramirez, W., Mills, A. M., Huckestein, B. R., Anderson, M., Pangburn, M. M., Lang, E. Y., Mullett, S. J., Chuan, B. W., Guo, L., et al. (2022) · Current Research in Physiology · doi:10.1016/j.crphys.2022.05.003 · Cited by 19 · see citing works
Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus
Anderson, J. E., Wright, E. E., & Shaefer, C. F. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0211-x · Cited by 19 · see citing works
SGLT2 Inhibitors and the Mechanisms Involved in Weight Loss
Feder, D., Gouveia, M. R. D. F. V., Govato, T. C. P., & Nassis, C. D. Z. (2020) · Current Pharmacology Reports · doi:10.1007/s40495-020-00236-3 · Cited by 18 · see citing works
Bouchi, R., Sonoda, N., Itoh, J., Ono, Y., Fukuda, T., Takeuchi, T., Kishimoto, J., Yamada, T., & Ogawa, Y. (2020) · Endocrine Journal · doi:10.1507/endocrj.ej20-0599 · Cited by 18 · see citing works
Ünal, İ., Cansız, D., Beler, M., Sezer, Z., Güzel, E., & Emekli‐Alturfan, E. (2023) · Brain Research · doi:10.1016/j.brainres.2023.148536 · Cited by 17 · see citing works
Noh, H., Joo, S. Y., Kim, C. H., Choi, S.-W., Lee, C. H., & Hwang, J. K. (2024) · Clinical Research in Cardiology · doi:10.1007/s00392-024-02389-3 · Cited by 17 · see citing works
Lam, K. S. L., Chow, C. C., Tan, K. C. B., Ronald, C. W., Kong, A. P. S., Tong, P. C. Y., Tsang, M. W., Chan, T. M., Tang, S. C. W., Lee, K. K., et al. (2016) · Current Medical Research and Opinion · doi:10.1185/03007995.2016.1161608 · Cited by 17 · see citing works
Liu, Z., Wu, X., Wang, Q., Li, Z., Liu, X., Sheng, X., Zhu, H., Zhang, M., Xu, J., Feng, X., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.922885 · Cited by 16 · see citing works
Hanson, P., Randeva, H. S., Cuthbertson, D. J., O'Hare, P. J., Parsons, N., Chatha, K. K., Reidy, G., Weickert, M. O., & Barber, T. M. (2022) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.381 · Cited by 15 · see citing works
AlZaim, I., Eid, A. H., Abd‐Elrahman, K. S., & EL‐Yazbi, A. F. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115337 · Cited by 16 · see citing works
Aimo, A., Senni, M., Barison, A., Panichella, G., Passino, C., Bayés‐Genís, A., & Emdin, M. (2022) · Heart Failure Reviews · doi:10.1007/s10741-022-10228-8 · Cited by 16 · see citing works
Zhang, X., Zhang, Y., Sun, G., Li, Z., Tan, W., Fan, Y., Gao, W., & Zhang, G. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132359 · Cited by 13 · see citing works
Long-Term Treatment with Empagliflozin Attenuates Renal Damage in Obese Zucker Rat
Manne, N. D. P. K., Ginjupalli, G. K., Rice, K. M., Arvapalli, R., Graffeo, V. A., Bandarupalli, V. V. K., & Blough, E. R. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0815-4908 · Cited by 13 · see citing works
Chowdhary, A., Thirunavukarasu, S., Jex, N., Coles, L., Bowers, C., Sengupta, A., Swoboda, P., Witte, K., Cubbon, R., Xue, H., et al. (2022) · Obesity · doi:10.1002/oby.23413 · Cited by 10 · see citing works
Multiple Benefits of Empagliflozin in PCOS: Evidence from a Preclinical Rat Model
Rakic, D., Jakovljevic, V. L., Zivkovic, V., Uzelac, J. J., Jovic, N., Muric, M. D., Pindović, B., Dimitrijević, A., Arsenijević, P. S., Rakic, J., et al. (2024) · Pathophysiology · doi:10.3390/pathophysiology31040041 · Cited by 11 · see citing works
Ishiwata, S., Kasai, T., Sato, A., Suda, S., Matsumoto, H., Shitara, J., Yatsu, S., Murata, A., Shimizu, M., Kato, T., et al. (2024) · Hypertension Research · doi:10.1038/s41440-024-01982-3 · Cited by 11 · see citing works
Effect of empagliflozin on weight in patients with prediabetes and diabetes
Sanjari, M., Hadavizadeh, M., Sadeghi, N., & Naghibzadeh‐Tahami, A. (2025) · Scientific Reports · doi:10.1038/s41598-024-83820-7 · Cited by 11 · see citing works
Papaetis, G. S., Picolos, M. K., & Sacharidou, A. (2025) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad/202298 · Cited by 11 · see citing works
Nuevos hipoglucemiantes orales y riesgo cardiovascular. Cruzando la frontera metabólica
Dalama, B., & Mesa, J. (2016) · Revista Española de Cardiología · doi:10.1016/j.recesp.2016.07.029 · Cited by 11 · see citing works
Cardiovascular outcomes in diabetic kidney disease: insights from recent clinical trials
Rocha, N. A., & McCullough, P. A. (2017) · Kidney International Supplements · doi:10.1016/j.kisu.2017.10.004 · Cited by 11 · see citing works
Cai, Y., Shi, W., & Xu, G. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1817378 · Cited by 11 · see citing works
Lee, M. H., Neeland, I. J., Rocha, N. D. A., Hughes, C., Malloy, C. R., & Jin, E. S. (2021) · Metabolism Open · doi:10.1016/j.metop.2021.100161 · Cited by 11 · see citing works
New Oral Hypoglycemic Agents and Cardiovascular Risk. Crossing the Metabolic Border
Dalama, B., & Mesa, J. (2016) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2016.07.008 · Cited by 11 · see citing works
Hussain, M., Elahi, A., Iqbal, J., Ghafoor, M. B., Rehman, H., & Akhtar, S. (2021) · Cureus · doi:10.7759/cureus.14268 · Cited by 10 · see citing works
Althobaiti, F. M., Alsanosi, S., Falemban, A. H., Alzahrani, A. R., Fataha, S. A., Salih, S. O., Alrumaih, A. M., Alotaibi, K. N., Althobaiti, H. M., Alghamdi, S., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11164769 · Cited by 10 · see citing works
Strategies and methods for the correction of obesity and associated cardiovascular risk
Kuznetsova, Т. Y., Druzhilov, М. A., Chumakova, G. A., & Veselovskaya, N. G. (2019) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2019-4-61-67 · Cited by 9 · see citing works
Varshney, A., & Rawat, R. (2023) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.20230090 · Cited by 9 · see citing works
Rizos, C. V., Filippatos, T. D., & Elisaf, M. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1418325 · Cited by 9 · see citing works
Alqudsi, M., Velez, J. C. Q., & Navarrete, J. E. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000865 · Cited by 9 · see citing works
- Authors
- Neeland, I. J., McGuire, D. K., Chilton, R., Crowe, S., Lund, S. S., Woerle, H. J., Broedl, U. C., & Johansen, O. E.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- The University of Texas at San Antonio Health Science Center (US)
- Boehringer Ingelheim (Germany) (DE)
- Boehringer Ingelheim (Norway) (NO)
- Corresponding author
- Neeland, Ian J
- Venue
- Diabetes and Vascular Disease Research
- Publisher
- SAGE Publications
- Published
- 2015-12-01
- Volume
- 13
- Issue
- 2
- Pages
- 119-126
- ISSN
- 1479-1641 (ISSN-L)
- 1752-8984
- PMC
- PMC4768401
- OpenAlex
- W2294512307
- Cited by
- 168
- References
- 25
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 11 · 2023: 19 · 2022: 18 · 2021: 20 · 2020: 24 · 2019: 17 · 2018: 18 · 2017: 9 · 2016: 11 · 2015: 2
- FWCI
- 11.56
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Diabetes and Vascular Disease Research (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (K23DK106520)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- empagliflozin, type 2 diabetes, weight loss, adiposity, waist circumference, visceral fat, abdominal obesity, total body fat, SGLT2 inhibitors, cardiometabolic risk
- MeSH terms
- Adult, Aged, Benzhydryl Compounds, Blood Glucose, Diabetes Mellitus, Type 2, Female, Glucosides, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Obesity, Weight Loss, Body Mass Index, Adiposity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
